Lokelma Dosing for Non-Chronic Hyperkalemia with eGFR 11 mL/min and K 5.3
For a patient with eGFR 11 mL/min (not on dialysis) and potassium 5.3 mmol/L without chronic hyperkalemia, start Lokelma (sodium zirconium cyclosilicate) at 10 g three times daily for up to 48 hours, then transition to 10 g once daily for maintenance. 1
Initial Correction Phase Dosing
The FDA-approved dosing for initial treatment of hyperkalemia is 10 g administered three times daily for up to 48 hours, regardless of renal function 1. This applies to your patient with:
- eGFR 11 mL/min (Stage 5 CKD, not yet on dialysis)
- Potassium 5.3 mmol/L (mild hyperkalemia)
- Non-chronic presentation
Key point: The standard 10 g TID dosing does NOT require adjustment based on eGFR in non-dialysis patients. The FDA label makes no distinction for severe CKD in the correction phase 1.
Maintenance Phase Dosing
After achieving normokalemia (typically within 24-48 hours), transition to 10 g once daily 1. Monitor serum potassium closely and adjust:
- Titrate in 5 g increments at weekly intervals based on potassium levels
- Maintenance range: 5 g every other day to 15 g daily
- Decrease or discontinue if potassium falls below target range 1
Critical Considerations for Advanced CKD
This patient is NOT on dialysis yet, so use the standard non-dialysis dosing. However, be aware that:
- If this patient progresses to chronic hemodialysis, dosing changes to 5 g once daily on non-dialysis days only (or 10 g if K+ >6.5 mmol/L) 1
- Patients with eGFR <30 mL/min achieved similar efficacy to those with better renal function in clinical trials—82% achieved normokalemia within 24 hours and maintained it long-term 2
- The HARMONIZE trial demonstrated that 98% of patients achieved normokalemia within 48 hours with the 10 g TID regimen, with mean potassium dropping from 5.6 to 4.5 mmol/L 3, 4
Monitoring and Safety
Monitor for edema closely in this patient with severe CKD. Each 5 g dose contains approximately 400 mg sodium 1. While edema was generally mild-to-moderate in trials and more common at 15 g daily doses 3, 1, patients with advanced CKD are at higher risk for fluid overload.
Watch for hypokalemia during treatment. In maintenance trials, 10-11% of patients on 10-15 g daily developed hypokalemia 4. Given this patient's severe CKD, they may be prone to acute illnesses that increase hypokalemia risk 1.
Separate other oral medications by at least 2 hours before or after Lokelma administration due to potential binding interactions 1.
Why This Dosing Strategy
The evidence strongly supports starting with 10 g TID regardless of CKD stage:
- Population pharmacodynamic modeling showed no clinically meaningful need for dose adjustment based on eGFR 5
- Long-term safety data (up to 12 months) in patients with Stage 4-5 CKD showed comparable efficacy and safety to those with milder CKD 2, 6
- The rapid onset of action (1 hour) and high efficacy make this the optimal approach even in severe CKD 3
Do not use the hemodialysis dosing regimen (5 g on non-dialysis days) unless the patient is actually receiving chronic hemodialysis 1.